John Boyce Email & Phone Number

Cambridge, MA, US

Cambridge, US

Co-founded and funded with Julian Robertson, Tiger Management.TigerGene LLC is a venture capital fund that forms and invests in the most promising early stage life science technologies, ranging from protein engineering platforms for therapeutic development, genomics tools, to AI and healthcare. TigerGene forms the companies around these technologies and.

Cambridge, US

BrickBio: a TigerGene formed and funded company focused on site specific conjugation at any site, with site specific multiple conjugations. BrickBio is exclusively working with therapeutic partners (pharma and bio-pharma). Exciting partnership just announced with Abcam to expand capabilities across both companies.

Cambridge, US

NanoMosaic is leveraging the power of nanoneedles for label free, single molecule detection of proteins across seven orders of dynamic range at a cost two orders of magnitude less than current protein interrogation solutions. With a simplified workflow and direct protein interrogation approach, NanoMosaic is poised to change the paradigm in diagnostics and.

Waltham, Massachusetts, US

Cambridge, Massachusetts, US

John teaches a class on innovation and entrepreneurship at Harvard. Students learn how to evaluate opportunities and raise capital by: examining company business models and thinking creatively, the actual step by step analysis of technology evaluation - what can be commercial and what should stay in academia, hands on technical and commercial evaluation of.

Waltham, MA, US

John was recently President and CEO of Exosome Diagnostics, a liquid biopsy company which he turned around and drove to a successful acquisition for $575 MM ($250 MM upfront) to Bio-Techne within ~2.5 years, resulting in a ~6X return to investors. John came to the company in October 2015 when the company was critically low on cash and struggling to close.

Cambridge, MA, US

John incorporated GnuBIO in December 2009, closed the Series A Round in November 2010, and began operations in January 2011. GnuBIO was acquired by Bio-Rad in April 2014, providing investors with a deal valued at ~6X ROI ($110 MM). GnuBIO/Bio-Rad is producing desktop DNA sequencing systems that provide "Sample In, Answer Out" ease of use to clinicians.

Delphi Bio was founded to serve the unmet need of providing strategic business planning and commercial positioning, by professionals who have worked for cutting edge biotechnology companies and who have developed detailed commercialization plans in competitive environments. Delphi Bio specializes in working with early stage start up companies in order to.

John founded, provided funding, and oversaw a staff to run the Consumer Genetics Conference which was the first, large scale, international, conference to thoroughly explore the emerging field of “Direct to Consumer” genetic testing. Through 2011 the conference grew to over 1,000 attendees and featured presentations from thought leaders such as Francis.

John was able to leverage the Series A raise of $6 MM in July 2008, and sell the company to Illumina in July 2010, providing investors with a ~5X ROI ($28 MM).John wrote the business strategy, planned the media and press release strategies, as well as set up the key scientific collaborations that enabled a successful exit for investors.John identified and.

Cambridge, MA, US

As Head of Business Development for Helicos BioSciences, John was responsible for identifying new market opportunities in which the company was able to develop new applications that gave it a substantial competitive advantage. As a result of this effort, John was able to identify both a market, as well as form a collaborative effort to develop an.

Santa Clara, California, US

Prior to Helicos, John was the Senior Director of Commercial Development for Parallele Biosciences, Inc. He played an integral role of building the company and orchestrating the sale of the company to Affymetrix for over $120MM within two years after the companies had formed a co-marketing agreement.

Westborough, Massachusetts, US

John served a distinguished and successful tenure as Director, United States Sales at Sequenom Inc., from FY 2000 to End FY 2003 where he initiated and led the successful expansion of Sequenom's MassARRAY system and consumable business in the United States. John was also responsible for designing and leading a business development and marketing initiative.

John was Head of Product Development and responsible for the development of the company's hollow fiber monoclonal antibody production system. He led a team of engineers and scientists to develop the product to market specifications, as well initiated and ran the company's beta program worldwide. He fostered and developed relationships in major.